Promoting autophagy to mitigate coronavirus disease pathology in the elderly
Author(s) -
Lund Da Costa Abby,
Mehta Het,
Mathur Ramkumar
Publication year - 2022
Publication title -
clinical and translational discovery
Language(s) - English
Resource type - Journals
ISSN - 2768-0622
DOI - 10.1002/ctd2.68
Subject(s) - autophagy , disease , immune system , coronavirus , covid-19 , immunity , medicine , immunology , virology , biology , infectious disease (medical specialty) , apoptosis , genetics
In this commentary, we highlight autophagy's important function, while identifying potential therapeutic targets for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the elderly. Autophagy's decline in the elderly causes increased cell senescence and a dysregulated immune system. As this demographic often faces decreased vaccine‐provided immunity, coronavirus disease 2019 treatments must be developed. We discuss a recent study by Acharya et al. (2022) that found that SF2523 induced autophagy, reducing SARS‐CoV‐2 replication. Furthermore, across varying dosages, SF2523 was shown to have a synergistic effect with remdesivir or MU‐UNMC. Consequently, we believe that SF2523, alone or with other anti‐virals, is a promising potential therapeutic for preventing SARS‐CoV‐2‐related mortalities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom